Đang tải... (xem toàn văn)
Nghiên cứu sự thay đổi chức năng tế bào bêta, độ nhạy insulin và kết quả can thiệp bằng thay đổi lối sống ở người tiền đái tháo đườngNghiên cứu sự thay đổi chức năng tế bào bêta, độ nhạy insulin và kết quả can thiệp bằng thay đổi lối sống ở người tiền đái tháo đườngNghiên cứu sự thay đổi chức năng tế bào bêta, độ nhạy insulin và kết quả can thiệp bằng thay đổi lối sống ở người tiền đái tháo đườngNghiên cứu sự thay đổi chức năng tế bào bêta, độ nhạy insulin và kết quả can thiệp bằng thay đổi lối sống ở người tiền đái tháo đườngNghiên cứu sự thay đổi chức năng tế bào bêta, độ nhạy insulin và kết quả can thiệp bằng thay đổi lối sống ở người tiền đái tháo đườngNghiên cứu sự thay đổi chức năng tế bào bêta, độ nhạy insulin và kết quả can thiệp bằng thay đổi lối sống ở người tiền đái tháo đườngNghiên cứu sự thay đổi chức năng tế bào bêta, độ nhạy insulin và kết quả can thiệp bằng thay đổi lối sống ở người tiền đái tháo đườngNghiên cứu sự thay đổi chức năng tế bào bêta, độ nhạy insulin và kết quả can thiệp bằng thay đổi lối sống ở người tiền đái tháo đườngNghiên cứu sự thay đổi chức năng tế bào bêta, độ nhạy insulin và kết quả can thiệp bằng thay đổi lối sống ở người tiền đái tháo đườngNghiên cứu sự thay đổi chức năng tế bào bêta, độ nhạy insulin và kết quả can thiệp bằng thay đổi lối sống ở người tiền đái tháo đườngNghiên cứu sự thay đổi chức năng tế bào bêta, độ nhạy insulin và kết quả can thiệp bằng thay đổi lối sống ở người tiền đái tháo đường
2018 2018 2, th 12 13 1.2 C , Error! Bookmark not defined 15 18 20 insulin, kháng insulin 22 1.3 C 1.3.1 25 25 27 insulin 31 35 38 38 38 39 43 43 43 45 45 46 49 56 61 62 63 65 65 65 66 67 67 67 72 79 79 84 86 93 93 93 95 97 97 103 108 108 113 insulin, kháng insulin sau 24 tháng 116 121 123 DANH M C CÁC CƠNG TRÌNH CƠNG B C UC TÀI, LU N ÁN O CÁC K T QU NGHIÊN ADA: BMI: BT: CNTB: CS: CT : GLP: HA: HATTh: HATTr: HHS: IDF: IFG: ) Impaired Fasting Glucose ( IGT: NG Normal Glucose (Glucose RLLM: THA: TG: Triglycerid YTNC: WHO: (World Health Organization) Trang 1.1 insulin, ch So sánh n nhóm ti 1.2 Phân b bào bêta, kháng insulin ng so v ng 21 ng nghiên c u theo nhóm ch ng can thi p 34 2.2 2.3 Phân lo i huy t áp theo JNC 59 r i lo n lipid theo tiêu chu n c a Hi p h a ng m ch Châu Âu (European Atherosclerosis Society EAS) 59 3.1 So sánh tu i, gi i c a nhóm b nh nhóm ch ng 65 3.2 Phân b t l ng nghiên c u theo nhóm tu i 65 3.3 m lâm sàng ch s nhân tr c ng so v i nhóm ch 3.4 m ch s huy t áp so v i nhóm ch nhóm ti n ng 66 nhóm ti ng ng 66 3.5 So sánh ch s sinh hóa máu gi a nhóm nghiên c u 67 3.6 T l y u t l i s ng i ti ng 67 3.7 T l y u t v ho ng th l c i ti ng 68 3.8 T l tình tr ng béo b ng theo gi i i ti 3.9 T l r i lo n lipid máu 3.10 Tóm t t t l m t s b nh, h i ch ng i ti ng 69 ng 70 i b nh ti n ng 71 3.11 So sánh giá tr gi i h n c a ch s insulin gi ti 3.12 ng nhóm ch ng 72 So sánh giá tr g i h n ch s HOMA2 gi ti 3.13 i ng nhóm ch T l kháng insulin, gi ng 72 nh y insulin suy gi m ch c bào bêta theo HOMA2 3.14 i i ti M a ch s insulin, ch bào bêta v i tu i ng 73 nh y i ti ng 74 3.15 So sánh trung bình ch s ch nh y insulin, bào bêta theo gi i i ti ng 74 3.16 Liên quan gi a ch s bào bêta v i th a cân nh y insulin, ch c béo phì i ti ng 75 3.17 Liên quan gi a ch s bào bêta v nh y insulin, ch c t áp i ti ng 75 3.18 Liên quan gi a ch s bào bêta v i béo b ng 3.19 nh y insulin, ch c i ti Liên quan gi a ch s bào bêta v i r i lo n lipid máu ng 76 nh y insulin, ch c i ti tháo ng 76 3.20 Liên quan gi a ch s nh y insulin, ch c bào bêta v i h i ch ng chuy n hóa (Theo ATPIII) 77 46 Ascaso J.F., Pardo S., Real J.T., et al (2003), Diagnosing Insulin Resistance by Simple Quantitative Methods in Subjects With Normal Glucose Metabolism, Diabetes Care, (26), pp.3320 25 47 Astrup A., Carraro R., Finer N., et al (2012), Safety, tolerability and sustained weight loss over years with the once-daily human GLP-1 analog, liraglutide, International journal of obesity, 36(6), pp.843-54 48 Bassuk S.S., Manson J.E (2005), Epidemiological evidence for the role of physical activity in reducing risk of type diabetes and cardiovascular disease, Journal of applied physiology, 99(3), pp.1193204 49 Basu A., Pedersen M.G., Cobelli C (2012), Prediabetes: Evaluation of Beta Cell Function, Diabetes Journal, 61(2), pp.270-71 50 Bock G., Dalla Man C., Campioni M., et al (2006), Pathogenesis of Pre-Diabetes: Mechanisms of Fasting and Postprandial Hyperglycemia in People With Impaired Fasting Glucose and/or Impaired Glucose Tolerance, Diabetes, (55), pp.3536 49 51 Bogardus C., Lillioja Stephen, Howard B.V., et al (1984), Relationships between insulin secretion, insulin action, and fasting plasma glucose concentration in nondiabetic and noninsulin-dependent diabetic subjects, Journal of Clinical Investigation, 74(4), pp.1238 52 Bonora E., Targher G., Alberiche M., et al (2000), Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity, Diabetes care, 23(1), pp.57-63 53 Bosch J., Yusuf S., Gerstein H.C., et al (2006), Effect of ramipril on the incidence of diabetes, N Engl J Med, 355(15), pp.1551-62 54 Boulé N.G., Haddad E., Kenny G.P., et al (2001), Effects of Exercise on Glycemic Control and Body Mass in Type Diabetes Mellitus, JAMA: The Journal of the American Medical Association, 286(10), pp.1218-27 55 Bradley C.L.A.R.E (1988), "Stress and diabetes", Handbook of life stress cognition and health, Chapter 21, pp.383-400 56 Bray G.A (2010), Control of Weight: How Do We Get Fat?, Textbook of Diabetes, Fourth Edition, pp.126-37 57 Burnet D.L., Elliott L.D., Quinn M.T., et al ( 2006), Preventing Diabetes in the Clinical Setting, J GEN INTERN MED, (21), pp.84 93 58 Chang A.M., Smith M.J., Bloem C.J., et al (2006), Limitation of the Cell Dysfunction in Older People, The Journal of Clinical Endocrinology & Metabolism, 91(2), pp.629-34 59 Chen H., Sullivan G., Quon M.J (2005), Assessing the Predictive Accuracy of QUICKI as a Surrogate Index for Insulin Sensitivity Using a Calibration Model, Diabetes care, (54), pp.1914-25 60 Cheng H.T., Huang J.W., Chiang C.K (2012), Metabolic syndrome and insulin resistance as risk factors for development of chronic kidney disease and rapid decline in renal function in elderly, The Journal of Clinical Endocrinology & Metabolism, 97(4), pp.1268-76 61 Chiasson J.L., Josse R.G., Gomis R., et al (2003), Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial, Jama, 290(4), pp.486-94 62 Chiasson J.L., Rabasa-Lhoret R (2004), Prevention of Type Diabetes Insulin Resistance and beta -Cell Function, Diabetes, 53(S3), pp.34-38 63 Chobanian A.V., Bakris G.L., Black H.R., et al (2003), Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure, Hypertension, 42(6), pp.1206-52 64 Cobelli C., Toffolo G.M., Dalla Man C., et al (2007), Assessment of -cell function in humans, simultaneously with insulin sensitivity and hepatic extraction, from intravenous and oral glucose tests, American Journal of Physiology-Endocrinology and Metabolism, 293(1), pp.E1E15 65 DeFronzo R.A., Abdul-Ghani M.A (2011), -cell function: the key to diabetes prevention, The Journal of Clinical Endocrinology & Metabolism, 96(8), pp.2354-66 66 DeFronzo R.A., Tripathy D., Schwenke D.C., et al (2011), Pioglitazone for diabetes prevention in impaired glucose tolerance, New England Journal of Medicine, 364(12), pp.1104-15 67 Diabetes Prevention Program Research Group (2003), Costs associated with the primary prevention of type diabetes mellitus in the diabetes prevention program, Diabetes care, 26(1), pp.36-47 68 Diabetes Prevention Program Research Group (2005), Role of insulin secretion and sensitivity in the evolution of type diabetes in the diabetes prevention program: effects of lifestyle intervention and metformin, Diabetes, 54(8), pp.2404 69 Diabetes Prevention Program Research Group (2009), 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study, Lancet (London, England), 374(9702), pp.1677-86 70 Diabetes Prevention Program Research Group (2002), Reduction in the incidence of type diabetes with lifestyle intervention or metformin, N Engl J Med, 346(6), pp.393-403 71 DREAM Trial Investigators (2006), Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial, The Lancet, 368(9541), pp.1096-105 72 DREAM Trial Investigators (2008), Effects of Ramipril and Rosiglitazone on Cardiovascular and Renal Outcomes in People With Impaired Glucose Tolerance or Impaired Fasting Glucose Results of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial, Diabetes Care, 31(5), pp.1007-14 73 Ferrannini E (1998), Insulin resistance versus insulin deficiency in non-insulin-dependent diabetes mellitus: problems and prospects, Endocrine Reviews, 19(4), pp.477-90 74 Ferrannini E., Gastaldelli A., Miyazaki Y., et al (2005), Beta-Cell Function in Subjects Spanning the Range from Normal Glucose Tolerance to Overt Diabetes: A New Analysis, J Clin Endocrinol Metab, 90(1), pp.493 500 75 Ferrannini E., Vichi S., Beck-Nielsen H., et al (1996), Insulin action and age: European Group for the Study of Insulin Resistance (EGIR), Diabetes, 45(7), pp.947-53 76 Fowler M.J (2010), Diagnosis, classification, and lifestyle treatment of diabetes, Clinical diabetes, 28(2), pp.79-86 77 Gastaldelli A., Ferrannini E., Miyazaki Y., et al (2004), Beta-cell dysfunction and glucose intolerance: results from the San Antonio metabolism (SAM) study, Diabetologia, 47(1), pp.31-39 78 Geloneze B., Vasques A.C., Stabe C.F., et al (2009), HOMA1-IR and HOMA2-IR indexes in identifying insulin resistance and metabolic syndrome: Brazilian Metabolic Syndrome Study (BRAMS), Arquivos Brasileiros de Endocrinologia & Metabologia, 53(2), pp.281-87 79 Gillies C.L., Abrams K.R., Lambert P.C., et al (2007), Pharmacological and lifestyle interventions to prevent or delay type diabetes in people with impaired glucose tolerance: systematic review and meta-analysis, Bmj, 334(7588), pp.299 80 Gujral U.P., Narayan K.M., Kahn S.E., et al (2014), The relative -cell function and insulin sensitivity with glycemic status and incident glycemic progression in migrant Asian Indians in the United States: The MASALA study, Journal of diabetes and its complications, 28(1), pp.45-50 81 Haffner S.M (1998), Epidemiology of type diabetes: risk factors, Diabetes care, 21(S3), pp.C3-C6 82 Hales C.N., Randle P.J (1963), Immunoassay of insulin with insulinantibody precipitate, Biochemical Journal, 88(1), pp.137 83 Harris S.B., Zinman B (2000), Primary prevention of type diabetes in high risk populations, Diabetes Care, (23), pp.879 81 84 Haus J.M., Solomon T.P., Marchetti C.M., et al (2010), Free fatty acid-induced hepatic insulin resistance is attenuated following lifestyle intervention in obese individuals with impaired glucose tolerance, The Journal of Clinical Endocrinology & Metabolism, 95(1), pp.323-27 85 Heymsfield S.B., Segal K.R., Hauptman J., et al (2000), Effects of weight loss with orlistat on glucose tolerance and progression to type diabetes in obese adults, Archives of Internal Medicine, 160(9), pp.1321-26 86 Holman R.R., Haffner S.M., McMurray J.J., et al (2010), Effect of nateglinide on the incidence of diabetes and cardiovascular events, New England Journal of Medicine, 362(16), pp.1463-76 87 Horton E.S (2010), Prevention of Type Diabetes Mellitus, Principles of diabetes mellitus, Springer, pp.821-32 88 Hu F.B., Stampfer M.J., Haffner S.M., et al (2002), Elevated Risk of Cardiovascular Disease Prior to Clinical Diagnosis of Type Diabetes, Diabetes Care, 25, pp.1129 34 89 Ilanne Parikka P., Eriksson J.G., Lindström J., et al (2004), Prevalence of the Metabolic Syndrome and Its Components Findings from a Finnish general population sample and the Diabetes Prevention Study cohort, Diabetes Care, 27(9), pp.2135-40 90 International Diabetes Federation (2010), A Guide to The National Diabetes Programs, International Diabetes Federation, pp.101 91 International Diabetes Federation (2013), IDF Diabetes Atlas: Sixth edition, Sixth edition 92 International Diabetes Federation (2015), IDF Diabetes Atlas: Seventh edition, IDF Diabetes Atlas, Seventh edition 93 Iqbal Hydrie M.Z., Basit A., Shera A.S., et al (2012), Effect of intervention in subjects with high risk of diabetes mellitus in Pakistan, Journal of nutrition and metabolism, pp.126 94 Jones P.M., Persaud S.J (2010), Islet Function and Insulin Secretion, Textbook of diabetes, pp.87 95 Kanat M., Mari A., Norton L., et al (2012), Distinct b-Cell Defects in Impaired Fasting Glucose and Impaired Glucose Tolerance, Diabetes, (61), pp.447-53 96 Katula J.A., Blackwell C.S., Rosenberger E.L., et al (2011), Translating Diabetes Prevention Programs: Implications for Dissemination and Policy, N C Med J, 72(5), pp.405-08 97 Katula J.A., Vitolins M.Z., Rosenberger E.L., et al (2011), Oneyear results of a community-based translation of the diabetes prevention program Healthy-Living Partnerships to Prevent Diabetes (HELP PD) project, Diabetes Care, 34(7), pp.1451-57 98 Katz A., Nambi S.S., Mather K., et al (2000), Quantitative Insulin Sensitivity Check Index: A Simple, Accurate Method for Assessing Insulin Sensitivity In Humans, The Journal of Clinical Endocrinology & Metabolism, 85(7), pp.2402-10 99 Levy J.C., Matthews D.R., Hermans M.P., et al (1998), Correct Homeostasis Model Assessment (HOMA) evaluation uses the computer program, Diabetes Care, (21), pp.2191-92 100 Li G., Zhang P., Wang J., et al (2008), The long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20-year follow-up study, Lancet, 371(9626), pp.1783-9 101 Lillioja S., Mott D.M., Spraul M., et al (1993), Insulin resistance and insulin secretory dysfunction as precursors of non-insulin-dependent diabetes mellitus: prospective studies of Pima Indians, New England Journal of Medicine, 329(27), pp.1988-92 102 Lily M., Godwin M (2009), Treating prediabetes with metformin systematic review and meta-analysis, Canadian Family Physician, 55(4), pp.363-69 103 Lorenzo C., Wagenknecht L.E., D'Agostino R.B., et al (2010), -Cell Dysfunction, and Conversion to Type Diabetes in a Multiethnic Population The Insulin Resistance Atherosclerosis Study, Diabetes Care, 33(1), pp.67-72 104 Ma R.C., Tong P.C (2010), Epidemiology of Type Diabetes, Textbook of Diabetes, pp.45-68 105 Marchetti P., Lupi R., Del Guerra S., et al (2009), Goals of -Cell preservation for glycemic control, Diabetes care, 32(S2), pp.S178-S83 106 Mari A., Schmitz O., Gastaldelli A., et al (2002), Meal and oral glucose tests for assessment of beta cell function: modeling analysis in normal subjects, Am J Physiol Endocrinol Metab, (283), pp.1159 66 107 Matte E.M., Velonakis E.G (2014), Type Diabetes Prevention Programs; How Far are we, J Diabetes Metab, 5(460), pp.2 108 Matthews D.R., Hosker J.P., Rudenski A.S., et al (1985), -cell function from fasting plasma glucose and insulin concentrations in man, Diabetologia, (28), pp.412-19 109 Meyer C., Pimenta W., Woerle H.J., et al (2006), Different Mechanisms for Impaired Fasting Glucose and Impaired Postprandial, Glucose Tolerance in Humans, Diabetes Care, (29), pp.1909-14 110 Nathan D.M., Buse J.B., Davidson M.B., et al (2009), Medical management of hyperglycaemia in type diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy, Diabetologia, 52(1), pp.17-30 111 NAVIGATOR Study Group., McMurray J.J., Holman R.R., et al (2010), Effect of valsartan on the incidence of diabetes and cardiovascular events, New England Journal of Medicine, 362(16), pp.1477-90 112 Ning F., Pang Z.C., Dong Y.H., et al (2009), Risk factors associated with the dramatic increase in the prevalence of diabetes in the adult Chinese population in Qingdao, China, Diabet Med, 26(9), pp.855-63 113 Nolan J.J., Ludvik B., Beerdsen P., et al (1994), Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone, New England Journal of Medicine, 331(18), pp.1188-93 114 Osei K., Rhinesmith S., Gaillard T., et al (2004), Impaired Insulin Sensitivity, Insulin Secretion, and Glucose Effectiveness Predict Future Development of Impaired Glucose Tolerance and Type Diabetes in Pre-Diabetic African Americans Implications for primary diabetes prevention, Diabetes Care, 27(6), pp.1439-46 115 Pacini G., Mari A (2003), Methods for clinical assessment of insulin -cell function, Best Practice & Research Clinical Endocrinology & Metabolism, 17(3), pp.305-22 116 Pan X.R., Li G.W., Hu Y.H., et al (1997), Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance The Da Qing IGT and Diabetes Study, Diabetes Care, 20(4), pp.537-44 117 Perreault L., Kahn S.E., Christophi C.A., et al (2009), Regression from pre-diabetes to normal glucose regulation in the diabetes prevention program, Diabetes Care, 32(9), pp.1583-88 118 Piccinni C., Motola D., Marchesini G., et al (2011), Assessing the association of pioglitazone use and bladder cancer through drug adverse event reporting, Diabetes care, 34(6), pp.1369-71 119 Polonsky K.S., Sturis J., Bell G.I (1996), Non-insulin-dependent diabetes mellitus a genetically programmed failure of the beta cell to compensate for insulin resistance, New England Journal of Medicine, 334(12), pp.777-83 120 Radziuk J (2014), Homeostastic model assessment and insulin sensitivity/resistance, Diabetes, 63(6), pp.1850-54 121 Ramachandran A., Snehalatha C., Mary S., et al (2006), The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1), Diabetologia, 49(2), pp.289-97 122 Reaven G.M (1988), Role of insulin resistance in human disease, Diabetes, 37(12), pp.1595-607 123 Roberts K.C., Shields M., de Groh M., et al (2012), Overweight and obesity in children and adolescents: results from the 2009 to 2011 Canadian Health Measures Survey, Health rep, 23(3), pp.37-41 124 Rose G (1985), Sick individuals and sick populations, Int J Epidemiol, (14), pp.32 38 125 Rosenberger Hale E., Goff D.C., Isom S., et al (2013), Relationship of weekly activity minutes to metabolic syndrome in prediabetes: the healthy living partnerships to prevent diabetes, Journal of physical activity & health, 10(5), pp.690 126 Rosenstock J., Klaff L.J., Schwartz S., et al (2010), Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre-diabetes, Diabetes Care, 33(6), pp.1173-75 127 Sakane N., Sato J., Tsushita K., et al (2011), Prevention of type diabetes in a primary healthcare setting: Three-year results of lifestyle intervention in Japanese subjects with impaired glucose tolerance, BMC Public Health, (11), pp.40-45 128 Satterfield D.W., Volansky M., Caspersen C.J., et al (2003), Community-Based Lifestyle Interventions to Prevent Type Diabetes, Diabetes Care, (26), pp.2643 52 129 Sjöström L., Lindroos A.K., Peltonen M., et al (2004), Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery, New England Journal of Medicine, 351(26), pp.2683-93 130 Sjöström L., Peltonen M., Jacobson P., et al (2012), Bariatric surgery and long-term cardiovascular events, Jama, 307(1), pp.56-65 131 Surwit R.S., Schneider M.S., Feinglos M.N (1992), Stress and diabetes mellitus, Diabetes care, 15(10), pp.1413-22 132 Tabák A.G., Herder C., Rathmann W., et al (2012), Prediabetes: a high-risk state for diabetes development, The Lancet, 379(9833), pp.2279-90 133 Tabák A.G., Jokela M., Akbaraly T.N., et al (2009), Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type diabetes: an analysis from the Whitehall II study, The Lancet, 373(9682), pp.2215-21 134 Tattersall R.B (2010), The history of diabetes mellitus, Textbook of Diabetes, Fourth Edition, pp.1-23 135 Torréns J.I., Skurnick J., Davidow A.L., et al (2004), Ethnic -cell Function in Premenopausal or Early Perimenopausal Women Without Diabetes, Diabetes Care, 27(2), pp.354-61 136 Tseng C.H (2012), Pioglitazone and Bladder Cancer A populationbased study of Taiwanese, Diabetes care, 35(2), pp.278-80 137 Tuomilehto J., Lindstrom J., Eriksson J.G., et al (2001), Finnish Diabetes Prevention Study Group Prevention of type diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance, N Engl J Med, 344(18), pp.1343-50 138 Tuomilehto J., Schwarz Peter, Lindström J (2011), Long-term benefits from lifestyle interventions for type diabetes prevention time to expand the efforts, Diabetes Care, 34(S2), pp.S210-S14 139 Turner R.C., Millns H., Neil H.A.W., et al (1998), Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23), Bmj, 316(7134), pp.823-28 140 Wallace T.M., Levy J.C., Matthews D.R (2004), Use and Abuse of HOMA modeling, Diabetes Care, 27(6), pp.1487-95 141 Wan Q., Wang F., Guan Q., et al (2010), Regression to normoglycaemia by fenofibrate in pre diabetic subjects complicated with hypertriglyceridaemia: a prospective randomized controlled trial, Diabetic Medicine, 27(11), pp.1312-17 142 Wei M., Gibbons L.W., Mitchell T.L., et al (2000), Alcohol intake and incidence of type diabetes in men, Diabetes Care, 23(1), pp.1822 143 Weir G.C., Bonner-Weir S (2004), Five stages of evolving beta-cell dysfunction during progression to diabetes, Diabetes, 53(3), pp.S16S21 144 Weyer C., Bogardus C., Mott D.M., et al (1999), The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type diabetes mellitus, The Journal of clinical investigation, 104(6), pp.787-94 145 Wierup N., Sundler F., Heller R.S (2014), The islet ghrelin cell, Journal of Molecular Endocrinology, (52), pp.R35 R49 146 Wilcox G (2005), Insulin and insulin resistance, Clinical biochemist reviews, 26(2), pp.19-39 147 Wild S., Roglic G., Green A (2004), Global prevalence of diabetes: estimates for the year 2000 and projections for 2030, Diabetes Care, 27(5), pp.1047-53 148 World Health Organization (2006), Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia : report of a WHO/IDF consultation, World Health Organization 149 World Health Organization (2011), Use of Glycated Haemoglobin (HbA1c) in the Diagnosis of Diabetes Mellitus, Publications of the World Health Organization 150 Xiao J., Weng J., Ji L., et al (2014), -cell Function and Better Insulin Sensitivity in Older Chinese Without Diabetes, J Gerontol A Biol Sci Med Sci, 69(4), pp.463 70 151 Yki-Järvinen H (2010), Insulin resistance in type diabetes, Textbook of Diabetes, Fourth Edition, pp.174-90 152 Yokoyama H., Emoto M., Fujiwara S., et al (2003), Quantitative Insulin Sensitivity Check Index and the Reciprocal Index of Homeostasis Model Assessment in Normal Range Weight and Moderately Obese Type Diabetic Patients, Diabetes Care, (26), pp.2426 32 153 Younis N., Soran H., Farook S (2004), The prevention of type diabetes mellitus: recent advances, Q J Med, (97), pp.451-55 cho Quy trình Phê ) n ... ti ng sau can thi p 86 3.34 S in trung bình ch s ch bào nh y insulin, kháng insulin sau can thi p 86 3.35 So sánh s i ch s insulin, ch bào bêta, nh y insulin, kháng insulin gi... 1.2.1 bào Bêta, nh y insulin nh y insulin, kháng insulin L ch s khái ni m - [146] [122] [82] , glucose máu bào insulin máu Các i ti ng 16 THA béo -C ( [146] Sinh b nh h c c a gi m nh y insulin, ... Trang m nghiên c u 36 [104] Theo , % [92] ( , ó, - glucose có g glucose máu , [5],[62],[92] phát [153] [92] Tuy nhiên (CT) insulin có [62] tài bêta, insulin , insulin kháng insulin Bình tháng